Clinical trial
Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by…
NCT00484432 · AGC Biologics S.p.A., Industry · Completed
Key facts
| NCT number | NCT00484432 |
|---|---|
| Title | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer |
| Official title | NGR012: A Phase II Study of NGR-hTNF Administered in Combination With Doxorubicin Every 3 Weeks in Patients Affected by Advanced or Metastatic Ovarian Cancer |
| Lead sponsor | AGC Biologics S.p.A., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer Metastatic Recurrent |
| Intervention type | Drug |
| Interventions | NGR-hTNF, doxorubicin |
| Enrollment | 37 |
| Start date | Nov 1, 2008 |
| Primary completion | Jun 1, 2016 |
| Completion | Jun 1, 2016 |
| First posted | Jun 8, 2007 |
| Last update posted | Sep 27, 2018 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: